1. Verma D, O'Brien S, Thomas D, et al. 2009; Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer. 115:101–6. DOI:
10.1002/cncr.24005. PMID:
19090005. PMCID:
PMC4180242.
Article
2. Morton LM, Dores GM, Tucker MA, et al. 2013; Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood. 121:2996–3004. DOI:
10.1182/blood-2012-08-448068. PMID:
23412096. PMCID:
PMC3624944.
Article
3. Kayser S, Döhner K, Krauter J, et al. 2011; The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 117:2137–45. DOI:
10.1182/blood-2010-08-301713. PMID:
21127174.
Article
4. Wu B, Jug R, Luedke C, et al. 2017; Lineage switch between B-lymphoblastic leukemia and acute myeloid leukemia intermediated by "Occult" myelodysplastic neoplasm: two cases of adult patients with evidence of genomic instability and clonal selection by chemotherapy. Am J Clin Pathol. 148:136–47. DOI:
10.1093/ajcp/aqx055. PMID:
28898985.
5. Pagano L, Annino L, Ferrari A, et al. 1998; Secondary haematological neoplasm after treatment of adult acute lymphoblastic leukemia: analysis of 1170 adult ALL patients enrolled in the GIMEMA trials. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Br J Haematol. 100:669–76. DOI:
10.1046/j.1365-2141.1998.00616.x. PMID:
9531332.
6. Tavernier E, Le QH, de Botton S, et al. 2007; Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA-87 and LALA-94 trials. Cancer. 110:2747–55. DOI:
10.1002/cncr.23097. PMID:
17963265.
Article
7. Grosicki S, Barchnicka A, Bodzenta E, Haus O, Jaśkowiec A. 2013; Secondary acute myeloid leukemia (sAML) immediately after intensive chemotherapy of acute lymphoblastic leukemia (ALL). J Leuk. 1:1000102. DOI:
10.4172/2329-6917.1000102.
Article